Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | The importance of bridging therapy in follicular and mantle cell lymphoma

Nicolaus Kröger • 28 Oct 2022
COSTEM 2022
Follicular Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Bendamustine CAR-T

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, briefly comments on the importance of bridging CAR-T therapy in relapsed/refractory (R/R) patients with mantle cell lymphoma (MCL) and follicular lymphoma (FL). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicolaus Kröger

1:23
COSTEM 2023: congress highlights and importance
Nicolaus Kröger • 21 Oct 2023
1:31
CAR-T therapy versus autoSCT in DLBCL
Nicolaus Kröger • 28 Oct 2022
0:51
The need for disease-modifying drugs in myelofibrosis
Nicolaus Kröger • 28 Oct 2022
1:36
The role of molecular markers in patient selection for transplantation in myelofibrosis
Nicolaus Kröger • 28 Oct 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals